G. Treadway et A. Reisman, Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases, INT J ANT A, 18(5), 2001, pp. 427-431
Tolerability of azithromycin oral suspension, 10 mg/kg once daily for 3 day
s, was assessed in paediatric patients (less than or equal to 18 years) wit
h respiratory or skin and soft-tissue infections. Of 2425 patients evaluate
d, 1213 received azithromycin and 1212 received standard regimens of amoxyc
illin; clavulanic acid, cefaclor, cefixime, ceftriaxone, clarithromycin, er
ythromycin, or penicillin V. The incidence of treatment-related adverse eve
nts was significantly lower in patients receiving azithromycin than compara
tors (7.9 vs. 11.5%, P = 0.003), while discontinuation rates were similar (
1.0 and 1.1%, respectively). Significantly fewer gastrointestinal events we
re recorded for azithromycin than comparators (6.5 vs. 9.9%, P = 0.002), an
d their duration was significantly shorter (mean 2.3 vs. 5.0 days, P = 0.00
01). Azithromycin paediatric oral suspension is well tolerated and associat
ed with significantly fewer adverse events than comparators. (C) 2001 Elsev
ier Science B.V. and International Society of Chemotherapy. All rights rese
rved.